Medicinal cannabis information group CB2 Insights Inc (CSE:CBII) (OTCQB:CBIIF) has announced it is expanding its industry presence in the UK, boosting CBII stock by five%.

The business, which specializes in study and information collection to give a suite of technologies options in the medicinal cannabis market, has mentioned it will license its technologies to MyAccess Clinics (MAC) to handle their patient information. MAC operates a number of clinics in the UK for sufferers looking for medicinal cannabis care due to traditional treatment options becoming ineffective. MAC will use CB2 Insights’ Electronic Information Capture Technologies (EDCT) to capture extensive information sets connected to patient overall health.

“The UK industry continues to blossom at a fast pace, and we are proud that our study and information technologies assets continue to be sought to expedite development in the industry,” mentioned Prad Sekar, Chief Executive Officer of CB2 Insights. “MyAccess Clinics has an exceptional and extensive vision for its improvement in the UK’s healthcare cannabis industry and we are excited to be a component of that work.” The status of cannabis in the UK is somewhat of a grey region, with medicinal cannabis technically becoming legalized final November to treat extreme instances of epilepsy.

>> MEDIF Stock Gains Soon after a Manufacturing Agreement with Cronos

CB2 Insights’ technologies is at the moment in use all through Canada and the US, with the aim of bringing typical healthcare protocols into the field of medicinal cannabis. The EDCT system works to simplify information input and management though making certain collection can in the end be employed to far better fully grasp the efficacy of cannabinoid therapy. Founded in 2014, the business is recognized as getting the largest cannabis patient registry across 13 states in the US, as effectively as an expanding international attain.

CB2 Insights started trading on the Canadia Securities Exchange (CSE) in March of this year, and it hasn’t been all plain sailing. The pot penny stock was initially valued about the $.25 mark but has subsequently lost more than 50% considering the fact that. Even so, investors will be hoping that expansions into emerging medicinal cannabis markets such as the UK’s will enable buoy CBII stock in the lengthy run.

Though you are right here, verify out our picks of some other promising cannabis penny stocks this month!

Featured Image: DepositPhotos © iqoncept